Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

gynaecology

  • Home
  •  
  • gynaecology



  • Most Read
  • Latest Comments
  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Genetic Technologies partners with CancerIQ to enhance cancer prevention but capital raise struggles
    Genetic Technologies partners with CancerIQ to enhance cancer prevention but capital raise struggles
    • News

  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • News

  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

  • Cleo Diagnostics progresses ovarian cancer test kits for US, Australia, and EU markets
    Cleo Diagnostics progresses ovarian cancer test kits for US, Australia, and EU markets
    • News

  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • News

    Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound

    A benchmarking study comparing ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV)’s blood test against ultrasound has been published in the scientific journal “Cancers” with positive outcomes.  The study found that Cleo’s initial test for the surgical triage market significantly outperforms the current clinical workflows that use Cancer Antigen 125 (CA125) and ultrasound to predict

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.